138 related articles for article (PubMed ID: 19077133)
1. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
Ayad E; Francis I; Peston D; Shousha S
Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
[No Abstract] [Full Text] [Related]
2. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
3. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
Tischkowitz M; Brunet JS; Bégin LR; Huntsman DG; Cheang MC; Akslen LA; Nielsen TO; Foulkes WD
BMC Cancer; 2007 Jul; 7():134. PubMed ID: 17650314
[TBL] [Abstract][Full Text] [Related]
4. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
5. Metaplastic breast carcinomas and their relationship with basal-like phenotype.
Cakir A; Gönül II; Uluoğlu O
Turk Patoloji Derg; 2012; 28(2):134-41. PubMed ID: 22627631
[TBL] [Abstract][Full Text] [Related]
6. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
[TBL] [Abstract][Full Text] [Related]
9. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
10. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
[TBL] [Abstract][Full Text] [Related]
11. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
12. Paired distribution of molecular subtypes in bilateral breast carcinomas.
Russnes HG; Kuligina ESh; Suspitsin EN; Voskresenskiy DA; Jordanova ES; Cornelisse CJ; Borresen-Dale AL; Imyanitov EN
Cancer Genet; 2011 Feb; 204(2):96-102. PubMed ID: 21504707
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer: clinicopathological characteristics and treatment strategies.
Akiyama F; Iwase H
Breast Cancer; 2009; 16(4):252-3. PubMed ID: 19506994
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
15. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
Sasa M; Bando Y; Takahashi M; Hirose T; Nagao T
J Surg Oncol; 2008 Jan; 97(1):30-4. PubMed ID: 17929254
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
Sidoni A; Cartaginese F; Colozza M; Gori S; Crinó L
Breast Cancer Res Treat; 2008 Oct; 111(3):569-70. PubMed ID: 17987380
[No Abstract] [Full Text] [Related]
17. Triple negative and basal-like breast cancer in East Africa.
Trinkaus ME; Sayed S; Gakinya SM; Moloo Z; Hanna W; Rahim Y
Breast J; 2011; 17(4):438-40. PubMed ID: 21752138
[No Abstract] [Full Text] [Related]
18. Clinicopathological characteristics of triple-negative breast cancers.
Sasaki Y; Tsuda H
Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
[TBL] [Abstract][Full Text] [Related]
19. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer molecular subtypes as identified by immunohistochemistry in South African black women.
van Bogaert LJ
Breast J; 2013; 19(2):210-1. PubMed ID: 23294416
[No Abstract] [Full Text] [Related]
[Next] [New Search]